Jaren Madden
Chief Corporate Affairs Officer and Head of Investor Relations
Replay available
Schrodinger, Inc. (NASDAQ: SDGR) Q2 2026 earnings conference call, held 2026-08-05. Replay captured from the company's public earnings webcast.

Chief Corporate Affairs Officer and Head of Investor Relations
Chief Executive Officer
Chief Financial Officer
President, Head of Therapeutics R&D and Chief Strategy Officer, Partnerships
Analyst, Bank of America
Analyst, Craig-Hallam Capital Group
Analyst, KeyBank
Chief Technology and Chief Operating Officer
Analyst, TD Cowen
Thank you for standing by. Welcome to Schrodinger's conference call to review second quarter 2026 financial results. My name is Rob and I will be your operator for today's call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star, then the number one on your telephone keypad. Please be advised that this call is being recorded at the company's request. Now I would like to introduce your host for today's conference, Ms. Jaren Madden, Chief Corporate Affairs Officer and Head of Investor Relations. Please go ahead. Thank you and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our second quarter 2026 financial results. Earlier today, we issued the press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com. During today's call, management will make statements that are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full year 2026 and Third Quarter 2026, our plans to accelerate the growth of our software business and advance our therapeutics portfolio, the capabilities and potential advantages of Bunsen, our agentic AI co-scientist, the clinical potential and properties of our and our collaborators' compounds, the use of our cash resources, as well as our future expenses. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information cu...